Meanwhile, Director of the Gamaleya Scientific Research Institute, Alexander Gintsburg, said that the second phase of tests of Russia's vaccine against COVID-19 will last until 28 July, and after that the institute will submit documents for registration.
The vaccine, produced by the country's Gamalei Institute of Epidemiology and Microbiology, went into clinical trials at Sechenov First Moscow State Medical University on June 18.
According to ClinicalTrials.gov, a registry recording all of the ongoing clinical studies, set up by the US National Library of Medicine, the Sechenov University study first began on June 18, and is listed as an "open two-stage non-randomised Phase 1 study with the participation of healthy volunteers".
"We worked with this vaccine, starting with preclinical studies and protocol development, and clinical trials are now underway", Tarasov noted.
A clinical trial for a vaccine has multiple phases.
The trial is expected to start in late July with at least five other large vaccine trials expected to be run through the COVID-19 Prevention Network and its more than 100 clinical trial sites.
Now, the latest development reported from Russian Federation indicates that some organizations have finally made the much-needed headway in developing a vaccine.
Mandatory Masks, Mickey At A Distance As Walt Disney World Reopens
In Orange County, where the resort is based, authorities have reported 16,630 cases - some of the highest numbers in the state. Disney World has reopened in Florida after being shut down for almost four months during the coronavirus pandemic.
"The research has been completed, and it proved that the vaccine is safe", Smolyarchuk said. In Phase II, the clinical study is expanded and the vaccine is given to people who have characteristics (such as age and physical health) similar to those for whom the new vaccine is intended.
Stanford and Harvard university-educated Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF), commented: "The Russian research base for vaccine development is one of the best globally, and we expect that the Russian vaccine will be one of the first in the world ready to be used", reported TrialSiteNews. As the third phase of human trials requires over 10,000 participants for the results to be valid, Thailand - due to its relatively low number of cases - will seek the cooperation of Brazil, India and Indonesia to carry out the tests.
TASS reported that "Both the first and second groups were forming an immune response after injections of the vaccine".
If all goes well with the vaccine in the next phases and it is approved for use, Gintsburg said that "about 50-60 million doses of the vaccine, or maybe even 70 million, will need to be produced in order to carry out mass coronavirus vaccination in Russian Federation".
People interested in volunteering will be asked to fill out a questionnaire meant to determine how likely they are to contract the coronavirus, with questions focusing on race, occupation and how many people they're exposed to on a regular basis, with an emphasis of recruiting people from communities that have been hit hardest from the virus.
Russian Federation has reported 719,449 cases and 11,188 deaths to date.